Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib Combined With Intrathecal Pemetrexed for Leptomeningeal Metastasis From EGFR-mutated NSCLC
NCT05810350Phase 2Completed
- Sponsor
- Three Gorges Hospital of Chongqing University
- Start
- Jan 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), leptomeningeal metastasis (LM), sponsored by Three Gorges Hospital of Chongqing University. Started Jan 2023; status: completed.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT05810350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810350.